Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Futura Medical ( (GB:FUM) ) has shared an announcement.
Futura Medical plc has announced its total issued share capital as 304,129,732 Ordinary Shares, which is also the total number of voting rights. This announcement is relevant for shareholders under the FCA’s Disclosure and Transparency Rules. The company continues to focus on its innovative sexual health products, with Eroxon being a key product addressing Erectile Dysfunction, a condition affecting a significant portion of the male population globally. Futura’s strategic partnerships in major markets enhance its industry positioning and potential market reach.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a pharmaceutical company specializing in the development of innovative sexual health products. Their core strength is in the research, development, and commercialization of topically delivered gel formulations, with their lead product Eroxon aimed at treating Erectile Dysfunction (ED). Eroxon is notable for being the only topical gel treatment for ED available over the counter, addressing significant unmet needs in the market. Futura has established distribution partnerships in major markets, including the US and Europe.
Average Trading Volume: 731,305
Technical Sentiment Signal: Sell
Current Market Cap: £28.85M
See more data about FUM stock on TipRanks’ Stock Analysis page.